Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-β-carboline: A new anti-Parkinson drug?

Expert Review of Neurotherapeutics

Volumn 11, Issue 6, 2011, Pages 845-860

  Polanski, Witold ^a   Reichmann, Heinz ^a   Gille, Gabriele ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

9 methyl carboline; anti inflammation; carbolines; dopaminergic neurons; neurite outgrowth; neuroprotection; neuroregeneration; neurostimulation; neurotrophic factors; Parkinson's disease

Indexed keywords

2,9 DIMETHYL BETA CARBOLINE; 9 METHYL BETA CARBOLINE; ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIPARKINSON AGENT; BETA CARBOLINE; BETA CARBOLINE DERIVATIVE; CILIARY NEUROTROPHIC FACTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DOPAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; HARMAN; HARMINE; HARMOL; HEAT SHOCK PROTEIN 25; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; NORMELINONINE F; NUCLEAR RECEPTOR RELATED FACTOR 1; PROTEIN KINASE C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; IN VITRO STUDY; NERVE FIBER GROWTH; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIPARKINSON AGENTS; BRAIN; CARBOLINES; DOPAMINE; HUMANS; NERVE REGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 79958281343     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.11.1     Document Type: Review

References (205)

1. Susilo R, Rommelspacher H. Formation of a b-carboline (1,2,3,4-tetrahydro-1-methyl-b-carboline-1-carboxylic acid) following intracerebroventricular injection of tryptamine and pyruvic acid. Naunyn Schmiedebergs Arch. Pharmacol. 335, 70-76 (1987). (Pubitemid 17000919)
2. Herraiz T, Galisteo J. Tetrahydro-b-carboline alkaloids occur in fruits and fruit juices. Activity as antioxidants and radical scavengers. J. Agric. Food Chem. 51, 7156-7161 (2003).
3. Gross GA, Turesky RJ, Fay LB, Stillwell WG, Skipper PL, Tannenbaum SR. Heterocyclic aromatic amine formation in grilled bacon, beef and fish and in grill scrapings. Carcinogenesis 14, 2313-2318 (1993). (Pubitemid 23335188)
4. Herraiz T, Chaparro C. Analysis of monoamine oxidase enzymatic activity by reversed-phase high performance liquid chromatography and inhibition by b-carboline alkaloids occurring in foods and plants. J. Chromatogr. A. 1120, 237-243 (2006). (Pubitemid 43866751)
5. Liao GZ, Wang GY, Xu XL, Zhou GH. Effect of cooking methods on the formation of heterocyclic aromatic amines in chicken and duck breast. Meat Sci. 85, 149-154 (2010).
6. Herraiz T, Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: b-carboline alkaloids act as potent and reversible inhibitors. Biochem. Biophys. Res. Commun. 326, 378-386 (2005). (Pubitemid 39593558)
7. Honecker H, Coper H, Fahndrich C, Rommelspacher H. Identification of tetrahydronorharmane (tetrahydro-b-carboline) in human blood platelets. J. Clin. Chem. Clin. Biochem. 18, 133-135 (1980). (Pubitemid 10184021)
8. Adachi J, Mizoi Y, Naito T, Ogawa Y, Uetani Y, Ninomiya I. Identification of tetrahydro-b-carboline-3-carboxylic acid in foodstuffs, human urine and human milk. J. Nutr. 121, 646-652 (1991).
9. Matsubara K, Kobayashi S, Kobayashi Y, et al. b-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 45, 2240-2245 (1995). (Pubitemid 27100255)
10. Herraiz T, Guillen H, Aran VJ. Oxidative metabolism of the bioactive and naturally occurring b-carboline alkaloids, norharman and harman, by human cytochrome P450 enzymes. Chem. Res. Toxicol. 21(11), 2172-2189 (2008).
11. Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson's disease. Neurology 66, S24-S36 (2006).
12. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med. 38, 333-347 (2006).
13. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM. Neuroinflammation and oxidation/nitration of a-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 28, 7687-7698 (2008).
14. Qian L, Flood PM, Hong JS. Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J. Neural Transm. 117, 971-979 (2010).
15. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285-1291 (1988).
16. Mastroeni D, Grover A, Leonard B, et al. Microglial responses to dopamine in a cell culture model of Parkinson's disease. Neurobiol. Aging 30, 1805-1817 (2009).
17. Gerhard A, Pavese N, Hotton G, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21, 404-412 (2006). (Pubitemid 43099863)
18. Ouchi Y, Yoshikawa E, Sekine Y, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann. Neurol. 57, 168-175 (2005). (Pubitemid 40179853)
19. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW. Association of circulating TNF-a and IL-6 with ageing and parkinsonism. Acta Neurol. Scand. 100, 34-41 (1999). (Pubitemid 29292549)
20. Neafsey EJ, Albores R, Gearhart D, et al. Methyl-b-carbolinium analogs of MPP+ cause nigrostriatal toxicity after substantia nigra injections in rats. Brain Res. 675, 279-288 (1995).
21. Ostergren A, Fredriksson A, Brittebo EB. Norharman-induced motoric impairment in mice: neurodegeneration and glial activation in substantia nigra. J. Neural Transm. 113, 313-329 (2006). (Pubitemid 43201098)
22. Polanski W, Enzensperger C, Reichmann H, Gille G. The exceptional properties of 9-methyl-b-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. J. Neurochem. 113, 1659-1675 (2010).
23. Hamann J, Rommelspacher H, Storch A, Reichmann H, Gille G. Neurotoxic mechanisms of 2,9-dimethyl-b-carbolinium ion in primary dopaminergic culture. J. Neurochem. 98, 1185-1199 (2006). (Pubitemid 44127794)
24. Hans G, Malgrange B, Lallemend F, et al. b-carbolines induce apoptosis in cultured cerebellar granule neurons via the mitochondrial pathway. Neuropharmacology 48, 105-117 (2005). (Pubitemid 40022920)
25. Funayama Y, Nishio K, Wakabayashi K, et al. Effects of b- and g-carboline derivatives of DNA topoisomerase activities. Mutat. Res. 349, 183-191 (1996).
26. Collins MA, Neafsey EJ, Matsubara K, Cobuzzi RJ, Jr, Rollema H. Indole-N-methylated b-carbolinium ions as potential brain-bioactivated neurotoxins. Brain Res. 570, 154-160 (1992).
27. Matsubara K, Collins MA, Akane A, et al. Potential bioactivated neurotoxicants, N-methylated b-carbolinium ions, are present in human brain. Brain Res. 610, 90-96 (1993). (Pubitemid 23144428)
28. Kuhn W, Muller T, Grosse H, Rommelspacher H. Elevated levels of harman and norharman in cerebrospinal fluid of Parkinsonian patients. J. Neural Transm. 103, 1435-1440 (1996). (Pubitemid 27023179)
29. Gearhart DA, Collins MA, Lee JM, Neafsey EJ. Increased b-carboline 9N-methyltransferase activity in the frontal cortex in Parkinson's disease. Neurobiol. Dis. 7, 201-211 (2000). (Pubitemid 30451034)
30. Stephens DN, Schneider HH, Kehr W, Jensen LH, Petersen E, Honore T. Modulation of anxiety by b-carbolines and other benzodiazepine receptor ligands: relationship of pharmacological to biochemical measures of efficacy. Brain Res. Bull. 19, 309-318 (1987). (Pubitemid 18014954)
31. Aricioglu F, Altunbas H. Harmane induces anxiolysis and antidepressant-like effects in rats. Ann. NY Acad. Sci. 1009, 196-201 (2003).
32. Farzin D, Mansouri N. Antidepressant-like effect of harmane and other b-carbolines in the mouse forced swim test. Eur. Neuropsychopharmacol. 16, 324-328 (2006). (Pubitemid 43898669)
33. Aricioglu F, Yillar O, Korcegez E, Berkman K. Effect of harmane on the convulsive threshold in epilepsy models in mice. Ann. NY Acad. Sci. 1009, 190-195 (2003). (Pubitemid 38265107)
34. Husbands SM, Glennon RA, Gorgerat S, et al. b-carboline binding to imidazoline receptors. Drug Alcohol Depend. 64, 203-208 (2001).
35. Robinson ES, Anderson NJ, Crosby J, Nutt DJ, Hudson AL. Endogenous b-carbolines as clonidine-displacing substances. Ann. NY Acad. Sci. 1009, 157-166 (2003).
36. Musgrave IF, Badoer E. Harmane produces hypotension following microinjection into the RVLM: possible role of I(1)- imidazoline receptors. Br. J. Pharmacol. 129, 1057-1059 (2000). (Pubitemid 30153959)
37. Sanchez-Blazquez P, Boronat MA, Olmos G, Garcia-Sevilla JA, Garzon J. Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br. J. Pharmacol. 130, 146-152 (2000). (Pubitemid 30248438)
38. Aricioglu F, Korcegez E, Ozyalcin S. Effect of harmane on mononeuropathic pain in rats. Ann. NY Acad. Sci. 1009, 180-184 (2003). (Pubitemid 38265105)
39. Cao R, Chen Q, Hou X, et al. Synthesis, acute toxicities, and antitumor effects of novel 9-substituted b-carboline derivatives. Bioorg. Med. Chem. 12, 4613-4623 (2004). (Pubitemid 39055982)
40. Kumar R, Gupta L, Pal P, et al. Synthesis and cytotoxicity evaluation of (tetrahydro-b-carboline)-1,3,5-triazine hybrids as anticancer agents. Eur. J. Med. Chem. 45, 2265-2276 (2010).
41. Formagio AS, Tonin LT, Foglio MA, et al. Synthesis and antitumoral activity of novel 3-(2-substituted-1,3,4-oxadiazol-5-yl) and 3-(5-substituted-1,2,4-triazol-3-yl) b-carboline derivatives. Bioorg. Med. Chem. 16, 9660-9667 (2008).
42. Chen X, Cromer BA, Lynch JW. Molecular determinants of b-carboline inhibition of the glycine receptor. J. Neurochem. 110, 1685-1694 (2009).
43. Touiki K, Rat P, Molimard R, Chait A, de Beaurepaire R. Harmane inhibits serotonergic dorsal raphe neurons in the rat. Psychopharmacology (Berl.) 182, 562-569 (2005). (Pubitemid 41464638)
44. Yang YJ, Lee JJ, Jin CM, Lim SC, Lee MK. Effects of harman and norharman on dopamine biosynthesis and l-DOPA-induced cytotoxicity in PC12 cells. Eur. J. Pharmacol. 587, 57-64 (2008).
45. Wernicke C, Schott Y, Enzensperger C, Schulze G, Lehmann J, Rommelspacher H. Cytotoxicity of b-carbolines in dopamine transporter expressing cells: structure-activity relationships. Biochem. Pharmacol. 74, 1065-1077 (2007). (Pubitemid 47299090)
46. Storch A, Hwang YI, Gearhart DA, et al. Dopamine transporter-mediated cytotoxicity of b-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake. J. Neurochem. 89, 685-694 (2004). (Pubitemid 38534154)
47. Ho BT, McIsaac WM, Tansey LW, Walker KE. Inhibitors of monoamine oxidase. 3. 9-substituted-b-carbolines. J. Pharm. Sci. 58, 219-221 (1969).
48. Rommelspacher H, Meier-Henco M, Smolka M, Kloft C. The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets. Eur. J. Pharmacol. 441, 115-125 (2002). (Pubitemid 34465697)
49. Rook Y, Schmidtke KU, Gaube F, et al. Bivalent b-carbolines as potential multitarget anti-Alzheimer agents. J. Med. Chem. 53(9), 3611-3617 (2010).
50. Rommelspacher H, May T, Susilo R. b-carbolines and tetrahydroisoquinolines: detection and function in mammals. Planta Med. 57, S85-S92 (1991).
51. Musshoff F, Daldrup T, Bonte W, Leitner A, Lesch OM. Formaldehyde-derived tetrahydroisoquinolines and tetrahydro-b-carbolines in human urine. J. Chromatogr. B Biomed. Appl. 683, 163-176 (1996). (Pubitemid 26319560)
52. McNaught KS, Carrupt PA, Altomare C, et al. Isoquinoline derivatives as endogenous neurotoxins in the aetiology of Parkinson's disease. Biochem. Pharmacol. 56, 921-933 (1998). (Pubitemid 28454556)
53. Okuda K, Kotake Y, Ohta S. Neuroprotective or neurotoxic activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline and related compounds. Bioorg. Med. Chem. Lett. 13, 2853-2855 (2003). (Pubitemid 37386238)
54. McNaught KS, Thull U, Carrupt PA, et al. Inhibition of complex I by isoquinoline derivatives structurally related to 1-methyl- 4-phenyl-1,2,3,6- tetrahydropyridine (MPTP). Biochem. Pharmacol. 50, 1903-1911 (1995). (Pubitemid 26011399)
55. Kobayashi H, Fukuhara K, Tada-Oikawa S, et al. The mechanisms of oxidative DNA damage and apoptosis induced by norsalsolinol, an endogenous tetrahydroisoquinoline derivative associated with Parkinson's disease. J. Neurochem. 108, 397-407 (2009).
56. Storch A, Ott S, Hwang YI, Ortmann R, et al. Selective dopaminergic neurotoxicity of isoquinoline derivatives related to Parkinson's disease: studies using heterologous expression systems of the dopamine transporter. Biochem. Pharmacol. 63, 909-920 (2002). (Pubitemid 34243004)
57. Kotake Y, Tasaki Y, Makino Y, Ohta S, Hirobe M. 1-Benzyl-1,2,3,4- tetrahydroisoquinoline as a Parkinsonism-inducing agent: a novel endogenous amine in mouse brain and Parkinsonian CSF. J. Neurochem. 65, 2633-2638 (1995).
58. Lorenc-Koci E, Smialowska M, Antkiewicz-Michaluk L, Golembiowska K, Bajkowska M, Wolfarth S. Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats. Neuroscience 95, 1049-1059 (2000). (Pubitemid 30006893)
59. Okuda K, Kotake Y, Ohta S. Parkinsonism-preventing activity of 1-methyl-1,2,3,4- tetrahydroisoquinoline derivatives in C57BL mouse in vivo. Biol. Pharm. Bull. 29, 1401-1403 (2006).
60. Yamakawa T, Ohta S. Biosynthesis of a parkinsonism-preventing substance, 1-methyl-1,2,3,4-tetrahydroisoquinoline, is inhibited by parkinsonism-inducing compounds in rat brain mitochondrial fraction. Neurosci. Lett. 259, 157-160 (1999). (Pubitemid 29059608)
61. Hamann J, Wernicke C, Lehmann J, Reichmann H, Rommelspacher H, Gille G. 9-methyl-b-carboline up-regulates the appearance of differentiated dopaminergic neurones in primary mesencephalic culture. Neurochem. Int. 52, 688-700 (2008).
62. Matsubara K, Gonda T, Sawada H, et al. Endogenously occurring b-carboline induces parkinsonism in nonprimate animals: a possible causative protoxin in idiopathic Parkinson's disease. J. Neurochem. 70, 727-735 (1998). (Pubitemid 28079363)
63. Wernicke C, Hellmann J, Zieba B, et al. 9-methyl-b-carboline has restorative effects in an animal model of Parkinson's disease. Pharmacol. Rep. 62, 35-53 (2010).
64. Greffard S, Verny M, Bonnet AM, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch. Neurol. 63, 584-588 (2006).
65. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J. Neural Transm. 38, 277-301 (1976).
66. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann. Neurol. 26, 551-557 (1989). (Pubitemid 19247232)
67. Ugrumov MV. Non-dopaminergic neurons partly expressing dopaminergic phenotype: distribution in the brain, development and functional significance. J. Chem. Neuroanat. 38, 241-256 (2009).
68. Kitahama K, Sakamoto N, Jouvet A, Nagatsu I, Pearson J. Dopamine-b-hydroxylase and tyrosine hydroxylase immunoreactive neurons in the human brainstem. J. Chem. Neuroanat. 10, 137-146 (1996). (Pubitemid 26177665)
69. Ikemoto K, Nagatsu I, Nishimura A, Nishi K, Arai R. Do all of human midbrain tyrosine hydroxylase neurons synthesize dopamine? Brain Res. 805, 255-258 (1998). (Pubitemid 29005141)
70. Ershov PV, Ugrumov MV, Calas A, Krieger M, Thibault J. Differentiation of tyrosine hydroxylase-synthesizing and/or aromatic l-amino acid decarboxylase-synthesizing neurons in the rat mediobasal hypothalamus: quantitative double-immunofluorescence study. J. Comp. Neurol. 446, 114-122 (2002). (Pubitemid 34252838)
71. Hynes M, Porter JA, Chiang C, et al. Induction of midbrain dopaminergic neurons by Sonic hedgehog. Neuron 15, 35-44 (1995).
72. Prakash N, Brodski C, Naserke T, et al. A Wnt1-regulated genetic network controls the identity and fate of midbrain-dopaminergic progenitors in vivo. Development 133, 89-98 (2006). (Pubitemid 43169323)
73. Castelo-Branco G, Wagner J, Rodriguez FJ, et al. Differential regulation of midbrain dopaminergic neuron development by Wnt-1, Wnt-3a, and Wnt-5a. Proc. Natl Acad. Sci. USA 100, 12747-12752 (2003). (Pubitemid 37339970)
74. Simon HH, Saueressig H, Wurst W, Goulding MD, O'Leary DD. Fate of midbrain dopaminergic neurons controlled by the engrailed genes. J. Neurosci. 21, 3126-3134 (2001). (Pubitemid 32323494)
75. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc. Natl Acad. Sci. USA 95, 4013-4018 (1998). (Pubitemid 28173245)
76. Maxwell SL, Ho HY, Kuehner E, Zhao S, Li M. Pitx3 regulates tyrosine hydroxylase expression in the substantia nigra and identifies a subgroup of mesencephalic dopaminergic progenitor neurons during mouse development. Dev. Biol. 282, 467-479 (2005). (Pubitemid 40799336)
77. Kadkhodaei B, Ito T, Joodmardi E, et al. Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J. Neurosci. 29, 15923-15932 (2009).
78. Le W, Pan T, Huang M, et al. Decreased Nurr1 gene expression in patients with Parkinson's disease. J. Neurol. Sci. 273, 29-33 (2008).
79. Ghee M, Baker H, Miller JC, Ziff EB. AP-1, CREB and CBP transcription factors differentially regulate the tyrosine hydroxylase gene. Brain Res. Mol. Brain Res. 55, 101-114 (1998). (Pubitemid 28236595)
80. Kim KS, Lee MK, Carroll J, Joh TH. Both the basal and inducible transcription of the tyrosine hydroxylase gene are dependent upon a cAMP response element. J. Biol. Chem. 268, 15689-15695 (1993). (Pubitemid 23222068)
81. Lewis-Tuffin LJ, Quinn PG, Chikaraishi DM. Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. Mol. Cell Neurosci. 25, 536-547 (2004). (Pubitemid 38366418)
82. Tsarovina K, Pattyn A, Stubbusch J, et al. Essential role of GATA transcription factors in sympathetic neuron development. Development 131, 4775-4786 (2004). (Pubitemid 39433464)
83. Hong SJ, Huh Y, Chae H, Hong S, Lardaro T, Kim KS. GATA-3 regulates the transcriptional activity of tyrosine hydroxylase by interacting with CREB. J. Neurochem. 98, 773-781 (2006). (Pubitemid 44051278)
84. Kwok RP, Lundblad JR, Chrivia JC, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370, 223-226 (1994). (Pubitemid 24236779)
85. Jiang H, Liu L, Yang S, Tomomi T, Toru N. CREB-binding proteins (CBP) as a transcriptional coactivator of GATA-2. Sci. China C. Life Sci. 51, 191-198 (2008). (Pubitemid 351208384)
86. Scherzer CR, Grass JA, Liao Z, et al. GATA transcription factors directly regulate the Parkinson's disease-linked gene a-synuclein. Proc. Natl Acad. Sci. USA 105, 10907-10912 (2008).
87. Dunkley PR, Bobrovskaya L, Graham ME, von Nagy-Felsobuki EI, Dickson PW. Tyrosine hydroxylase phosphorylation: regulation and consequences. J. Neurochem. 91, 1025-1043 (2004). (Pubitemid 39587442)
88. Cha-Molstad H, Keller DM, Yochum GS, Impey S, Goodman RH. Cell-type-specific binding of the transcription factor CREB to the cAMP-response element. Proc. Natl Acad. Sci. USA 101, 13572-13577 (2004). (Pubitemid 39238444)
89. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cell. Signal. 16, 1211-1227 (2004).
90. Hu SC, Chrivia J, Ghosh A. Regulation of CBP-mediated transcription by neuronal calcium signaling. Neuron 22, 799-808 (1999). (Pubitemid 29203502)
91. Du X, Iacovitti L. Multiple signaling pathways direct the initiation of tyrosine hydroxylase gene expression in cultured brain neurons. Brain Res. Mol. Brain Res. 50, 1-8 (1997). (Pubitemid 27488883)
92. Du X, Iacovitti L. Protein kinase C activators work in synergy with specific growth factors to initiate tyrosine hydroxylase expression in striatal neurons in culture. J. Neurochem. 68, 564-569 (1997). (Pubitemid 27044715)
93. Anastasiadis PZ, Kuhn DM, Blitz J, Imerman BA, Louie MC, Levine RA. Regulation of tyrosine hydroxylase and tetrahydrobiopterin biosynthetic enzymes in PC12 cells by NGF, EGF and IFN-g. Brain Res. 713, 125-133 (1996). (Pubitemid 26116257)
94. Fuxe K, Tinner B, Zoli M, et al. Computer-assisted mapping of basic fibroblast growth factor immunoreactive nerve cell populations in the rat brain. J. Chem. Neuroanat. 11, 13-35 (1996). (Pubitemid 26248749)
95. Ditlevsen DK, Owczarek S, Berezin V, Bock E. Relative role of upstream regulators of Akt, ERK and CREB in NCAM- and FGF2-mediated signalling. Neurochem. Int. 53, 137-147 (2008).
96. Ong SH, Hadari YR, Gotoh N, Guy GR, Schlessinger J, Lax I. Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins. Proc. Natl Acad. Sci. USA 98, 6074-6079 (2001). (Pubitemid 32488195)
97. Neiiendam JL, Kohler LB, Christensen C, et al. An NCAM-derived FGF-receptor agonist, the FGL-peptide, induces neurite outgrowth and neuronal survival in primary rat neurons. J. Neurochem. 91, 920-935 (2004). (Pubitemid 39507369)
98. Mograbi B, Bocciardi R, Bourget I, et al. Glial cell line-derived neurotrophic factor-stimulated phosphatidylinositol 3-kinase and Akt activities exert opposing effects on the ERK pathway: importance for the rescue of neuroectodermic cells. J. Biol. Chem. 276, 45307-45319 (2001).
99. Besset V, Scott RP, Ibanez CF. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase. J. Biol. Chem. 275, 39159-39166 (2000). (Pubitemid 32058932)
100. Soler RM, Dolcet X, Encinas M, Egea J, Bayascas JR, Comella JX. Receptors of the glial cell line-derived neurotrophic factor family of neurotrophic factors signal cell survival through the phosphatidylinositol 3-kinase pathway in spinal cord motoneurons. J. Neurosci. 19, 9160-9169 (1999). (Pubitemid 30228068)
101. Encinas M, Tansey MG, Tsui-Pierchala BA, Comella JX, Milbrandt J, Johnson EM Jr. c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)- dependent pathway. J. Neurosci. 21, 1464-1472 (2001). (Pubitemid 32182188)
102. Pong K, Xu RY, Baron WF, Louis JC, Beck KD. Inhibition of phosphatidylinositol 3-kinase activity blocks cellular differentiation mediated by glial cell line-derived neurotrophic factor in dopaminergic neurons. J. Neurochem. 71, 1912-1919 (1998). (Pubitemid 28491546)
103. Ries V, Cheng HC, Baohan A, et al. Regulation of the postnatal development of dopamine neurons of the substantia nigra in vivo by Akt/protein kinase B. J. Neurochem. 110, 23-33 (2009).
104. Ries V, Henchcliffe C, Kareva T, et al. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc. Natl Acad. Sci. USA 103, 18757-18762 (2006). (Pubitemid 44913483)
105. Maurer JA, Wray S. Neuronal dopamine subpopulations maintained in hypothalamic slice explant cultures exhibit distinct tyrosine hydroxylase mRNA turnover rates. J. Neurosci. 17, 4552-4561 (1997). (Pubitemid 27246913)
106. Chuang D, Zsilla G, Costa E. Turnover rate of tyrosine hydroxylase during trans-synaptic induction. Mol. Pharmacol. 11, 784-794 (1975).
107. Keller S, Reichmann H, Gille G. 9-methyl-b-carboline inhibits monoamine oxidase activity and stimulates the expression of growth factors by astrocytes. Mov. Disord. 25, 619 (2010).
108. Martinez R, Gomes FC. Neuritogenesis induced by thyroid hormone-treated astrocytes is mediated by epidermal growth factor/mitogen-activated protein kinase-phosphatidylinositol 3-kinase pathways and involves modulation of extracellular matrix proteins. J. Biol. Chem. 277, 49311-49318 (2002). (Pubitemid 36014361)
109. Williams EJ, Walsh FS, Doherty P. Tyrosine kinase inhibitors can differentially inhibit integrin-dependent and CAM-stimulated neurite outgrowth. J. Cell Biol. 124, 1029-1037 (1994). (Pubitemid 24109404)
110. Seidenfaden R, Krauter A, Hildebrandt H. The neural cell adhesion molecule NCAM regulates neuritogenesis by multiple mechanisms of interaction. Neurochem. Int. 49, 1-11 (2006). (Pubitemid 43669147)
111. Ditlevsen DK, Povlsen GK, Berezin V, Bock E. NCAM-induced intracellular signaling revisited. J. Neurosci. Res. 86, 727-743 (2008). (Pubitemid 351357755)
112. Wang DD, Bordey A. The astrocyte odyssey. Prog. Neurobiol. 86, 342-367 (2008).
113. Cao JP, Wang HJ, Yu JK, Yang H, Xiao CH, Gao DS. Involvement of NCAM in the effects of GDNF on the neurite outgrowth in the dopamine neurons. Neurosci. Res. 61, 390-397 (2008).
114. Zihlmann KB, Ducray AD, Schaller B, et al. The GDNF family members neurturin, artemin and persephin promote the morphological differentiation of cultured ventral mesencephalic dopaminergic neurons. Brain Res. Bull. 68, 42-53 (2005). (Pubitemid 41698875)
115. Beck KD. Functions of brain-derived neurotrophic factor, insulin-like growth factor-I and basic fibroblast growth factor in the development and maintenance of dopaminergic neurons. Prog. Neurobiol. 44, 497-516 (1994). (Pubitemid 24372701)
116. Hyman C, Juhasz M, Jackson C, Wright P, Ip NY, Lindsay RM. Overlapping and distinct actions of the neurotrophins BDNF, NT-3, NT-4/5 on cultured dopaminergic and GABAergic neurons of the ventral mesencephalon. J. Neurosci. 14, 335-347 (1994).
117. Krieglstein K, Strelau J, Schober A, Sullivan A, Unsicker K. TGF-b and the regulation of neuron survival and death. J. Physiol. Paris 96, 25-30 (2002). (Pubitemid 34087030)
118. Farkas LM, Dunker N, Roussa E, Unsicker K, Krieglstein K. Transforming growth factor-b(s) are essential for the development of midbrain dopaminergic neurons in vitro and in vivo. J. Neurosci. 23, 5178-5186 (2003). (Pubitemid 36793246)
119. Ben Gedalya T, Loeb V, Israeli E, Altschuler Y, Selkoe DJ, Sharon R. a-synuclein and polyunsaturated fatty acids promote clathrin-mediated endocytosis and synaptic vesicle recycling. Traffic 10, 218-234 (2009).
120. Sidhu A, Wersinger C, Vernier P. a-synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett. 565, 1-5 (2004). (Pubitemid 38595310)
121. Perez RG, Waymire JC, Lin E, Liu JJ, Guo F, Zigmond MJ. A role for a-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 22, 3090-3099 (2002). (Pubitemid 35379198)
122. Drolet RE, Behrouz B, Lookingland KJ, Goudreau JL. Substrate-mediated enhancement of phosphorylated tyrosine hydroxylase in nigrostriatal dopamine neurons: evidence for a role of a-synuclein. J. Neurochem. 96, 950-959 (2006).
123. Jensen PJ, Alter BJ, O'Malley KL. a-synuclein protects naive but not dbcAMP-treated dopaminergic cell types from 1-methyl-4-phenylpyridinium toxicity. J. Neurochem. 86, 196-209 (2003). (Pubitemid 36753860)
124. Yuan Y, Sun J, Zhao M, Hu J, Wang X, Du G, Chen NH. Overexpression of a-synuclein down-regulates BDNF expression. Cell Mol. Neurobiol. 30(6), 939-946 (2010).
125. Theodore S, Cao S, McLean PJ, Standaert DG. Targeted overexpression of human a-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease. J. Neuropathol. Exp. Neurol. 67, 1149-1158 (2008).
126. Vekrellis K, Xilouri M, Emmanouilidou E, Stefanis L. Inducible over-expression of wild type a-synuclein in human neuronal cells leads to caspase-dependent non-apoptotic death. J. Neurochem. 109, 1348-1362 (2009).
127. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593 (2006). (Pubitemid 44781171)
128. Imai Y, Gehrke S, Wang HQ, et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27, 2432-2443 (2008).
129. Tong Y, Yamaguchi H, Giaime E, et al. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of a-synuclein, and apoptotic cell death in aged mice. Proc. Natl Acad. Sci. USA 107, 9879-9884 (2010).
130. Anderson DW, Bradbury KA, Schneider JS. Neuroprotection in Parkinson models varies with toxin administration protocol. Eur. J. Neurosci. 24, 3174-3182 (2006). (Pubitemid 44952649)
131. Gao HM, Hong JS, Zhang W, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22, 782-790 (2002). (Pubitemid 34141759)
132. Schagger H, Pfeiffer K. Supercomplexes in the respiratory chains of yeast and mammalian mitochondria. EMBO J. 19, 1777-1783 (2000). (Pubitemid 30204389)
133. Stroh A, Anderka O, Pfeiffer K, et al. Assembly of respiratory complexes I, III, and IV into NADH oxidase supercomplex stabilizes complex I in Paracoccus denitrificans. J. Biol. Chem. 279, 5000-5007 (2004). (Pubitemid 38199096)
134. Schafer E, Seelert H, Reifschneider NH, Krause F, Dencher NA, Vonck J. Architecture of active mammalian respiratory chain supercomplexes. J. Biol. Chem. 281, 15370-15375 (2006). (Pubitemid 43855128)
135. Radad K, Gille G, Rausch WD. Dopaminergic neurons are preferentially sensitive to long-term rotenone toxicity in primary cell culture. Toxicol. In Vitro 22, 68-74 (2008). (Pubitemid 350267108)
136. Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643 (1978). (Pubitemid 8402469)
137. Bisaglia M, Tosatto L, Munari F, et al. Dopamine quinones interact with a-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 394, 424-428 (2010).
138. Hirai H, Pang Z, Bao D, et al. Cbln1 is essential for synaptic integrity and plasticity in the cerebellum. Nat. Neurosci. 8, 1534-1541 (2005). (Pubitemid 41573668)
139. Kusnoor SV, Muly EC, Morgan JI, Deutch AY. Is the loss of thalamostriatal neurons protective in parkinsonism? Parkinsonism Relat. Disord. 15(Suppl. 3), S162-S166 (2009).
140. Jiang Q, Yan Z, Feng J. Neurotrophic factors stabilize microtubules and protect against rotenone toxicity on dopaminergic neurons. J. Biol. Chem. 281, 29391-29400 (2006). (Pubitemid 44507082)
141. Bjorklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4, 186-200 (1997). (Pubitemid 27465509)
142. Spina MB, Squinto SP, Miller J, Lindsay RM, Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59, 99-106 (1992).
143. Lindholm P, Voutilainen MH, Lauren J, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448, 73-77 (2007). (Pubitemid 47037006)
144. Hagg T. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo. Exp. Neurol. 149, 183-192 (1998). (Pubitemid 28091027)
145. Li Z, Hu Y, Zhu Q, Zhu J. Neurotrophin-3 reduces apoptosis induced by 6-OHDA in PC12 cells through Akt signaling pathway. Int. J. Dev. Neurosci. 26, 635-640 (2008).
146. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann. Neurol. 46, 419-424 (1999). (Pubitemid 29416283)
147. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59, 459-466 (2006). (Pubitemid 43358066)
148. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60, 69-73 (2003). (Pubitemid 36070646)
149. Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Deliv. Rev. 60, 1527-1533 (2008).
150. Mallajosyula JK, Kaur D, Chinta SJ, et al. MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One 3, e1616 (2008).
151. Malorni W, Giammarioli AM, Matarrese P, et al. Protection against apoptosis by monoamine oxidase A inhibitors. FEBS Lett. 426, 155-159 (1998). (Pubitemid 28198175)
152. Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann. NY Acad. Sci. 939, 320-329 (2001). (Pubitemid 32620083)
153. Szende B, Bokonyi G, Bocsi J, Keri G, Timar F, Magyar K. Anti-apoptotic and apoptotic action of (-)-deprenyl and its metabolites. J. Neural Transm. 108, 25-33 (2001). (Pubitemid 32692611)
154. Zhang X, Zhou JY, Chin MH, et al. Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse model. J. Proteome Res. 9, 1496-1509 (2010).
155. Collins GG, Youdim MB. Multiple forms of human brain monoamine oxidase: substrate specificities. Biochem. J. 117, P43 (1970).
156. Youdim MB, Holman B. The nature of inhibition of cat brain mitochondrial monoamine oxidase by clorgyline. J. Neural Transm. 37, 11-24 (1975).
157. Westlund KN, Krakower TJ, Kwan SW, Abell CW. Intracellular distribution of monoamine oxidase A in selected regions of rat and monkey brain and spinal cord. Brain Res. 612, 221-230 (1993). (Pubitemid 23167283)
158. Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Br. J. Pharmacol. 147(Suppl. 1), S287-S296 (2006). (Pubitemid 43077287)
159. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003).
160. Golbe LI. a-synuclein and Parkinson's disease. Mov. Disord. 14, 6-9 (1999).
161. Henze C, Hartmann A, Lescot T, Hirsch EC, Michel PP. Proliferation of microglial cells induced by 1-methyl-4- phenylpyridinium in mesencephalic cultures results from an astrocyte-dependent mechanism: role of granulocyte macrophage colony-stimulating factor. J. Neurochem. 95, 1069-10772005). (Pubitemid 41713491)
162. Duffy HS, John GR, Lee SC, Brosnan CF, Spray DC. Reciprocal regulation of the junctional proteins claudin-1 and connexin43 by interleukin-1b in primary human fetal astrocytes. J. Neurosci. 20, RC114 (2000).
163. Wachtel M, Bolliger MF, Ishihara H, Frei K, Bluethmann H, Gloor SM. Down-regulation of occludin expression in astrocytes by tumour necrosis factor (TNF) is mediated via TNF type-1 receptor and nuclear factor-kB activation. J. Neurochem. 78, 155-162 (2001).
164. Conti B, Park LC, Calingasan NY, et al. Cultures of astrocytes and microglia express interleukin 18. Brain Res. Mol. Brain Res. 67, 46-52 (1999). (Pubitemid 29170067)
165. Sugama S, Cho BP, Baker H, Joh TH, Lucero J, Conti B. Neurons of the superior nucleus of the medial habenula and ependymal cells express IL-18 in rat CNS. Brain Res. 958, 1-9 (2002). (Pubitemid 35441207)
166. Prinz M, Hanisch UK. Murine microglial cells produce and respond to interleukin-18. J. Neurochem. 72, 2215-2218 (1999). (Pubitemid 29186031)
167. Sugama S, Fujita M, Hashimoto M, Conti B. Stress induced morphological microglial activation in the rodent brain: involvement of interleukin-18. Neuroscience 146, 1388-1399 (2007). (Pubitemid 46694135)
168. Felderhoff-Mueser U, Schmidt OI, Oberholzer A, Buhrer C, Stahel PF. IL-18: a key player in neuroinflammation and neurodegeneration? Trends Neurosci. 28, 487-493 (2005). (Pubitemid 41187798)
169. Flynn G, Maru S, Loughlin J, Romero IA, Male D. Regulation of chemokine receptor expression in human microglia and astrocytes. J. Neuroimmunol. 136, 84-93 (2003). (Pubitemid 36298847)
170. Dibaj P, Nadrigny F, Steffens H, et al. NO mediates microglial response to acute spinal cord injury under ATP control in vivo. Glia 58, 1133-1144 (2010).
171. Caggiano AO, Kraig RP. Eicosanoids and nitric oxide influence induction of reactive gliosis from spreading depression in microglia but not astrocytes. J. Comp. Neurol. 369, 93-108 (1996). (Pubitemid 26137483)
172. Ebadi M, Sharma SK. Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. Antioxid. Redox Signal. 5, 319-335 (2003). (Pubitemid 36793015)
173. Chen S, Brown IR. Neuronal expression of constitutive heat shock proteins: implications for neurodegenerative diseases. Cell Stress Chaperones 12, 51-58 (2007). (Pubitemid 47403328)
174. Acarin L, Paris J, Gonzalez B, Castellano B. Glial expression of small heat shock proteins following an excitotoxic lesion in the immature rat brain. Glia 38, 1-14 (2002).
175. Kakimura J, Kitamura Y, Takata K, et al. Microglial activation and amyloid-b clearance induced by exogenous heat-shock proteins. FASEB J. 16, 601-603 (2002). (Pubitemid 44793415)
176. Yoshida M, Xia Y. Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase. J. Biol. Chem. 278, 36953-36958 (2003). (Pubitemid 37140030)
177. Clerget M, Polla BS. Erythrophagocytosis induces heat shock protein synthesis by human monocytes-macrophages. Proc. Natl Acad. Sci. USA 87, 1081-1085 (1990).
178. Jeon GS, Park SW, Kim D, et al. Glial expression of the 90-kDa heat shock protein (HSP90) and the 94-kDa glucose-regulated protein (GRP94) following an excitotoxic lesion in the mouse hippocampus. Glia 48, 250-258 (2004). (Pubitemid 39545939)
179. Sriram K, Miller DB, O'Callaghan JP. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-a. J. Neurochem. 96, 706-718 (2006).
180. Trujillo JI, Meyers MJ, Anderson DR, et al. Novel tetrahydro-b-carboline- 1-carboxylic acids as inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg. Med. Chem. Lett. 17, 4657-4663 (2007). (Pubitemid 47061507)
181. Wu JP, Wang J, Abeywardane A, et al. The discovery of carboline analogs as potent MAPKAP-K2 inhibitors. Bioorg. Med. Chem. Lett. 17, 4664-4669 (2007). (Pubitemid 47058930)
182. Palma JP, Kim BS. The scope and activation mechanisms of chemokine gene expression in primary astrocytes following infection with Theiler's virus. J. Neuroimmunol. 149, 121-129 (2004). (Pubitemid 38352865)
183. Ambrosini E, Remoli ME, Giacomini E, et al. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 64, 706-715 (2005). (Pubitemid 41179012)
184. Ambrosini E, Aloisi F. Chemokines and glial cells: a complex network in the central nervous system. Neurochem. Res. 29, 1017-1038 (2004). (Pubitemid 39011351)
185. Mocco J, Mack WJ, Ducruet AF, et al. Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ. Res. 99, 209-217 (2006). (Pubitemid 44297045)
186. Diez M, Abdelmagid N, Harnesk K, et al. Identification of gene regions regulating inflammatory microglial response in the rat CNS after nerve injury. J. Neuroimmunol. 212, 82-92 (2009).
187. Gonzalez P, Burgaya F, Acarin L, Peluffo H, Castellano B, Gonzalez B. Interleukin-10 and interleukin-10 receptor-I are upregulated in glial cells after an excitotoxic injury to the postnatal rat brain. J. Neuropathol. Exp. Neurol. 68, 391-403 (2009).
188. Kremlev SG, Palmer C. Interleukin-10 inhibits endotoxin-induced pro-inflammatory cytokines in microglial cell cultures. J. Neuroimmunol. 162, 71-80 (2005).
189. Strle K, Zhou JH, Shen WH, Broussard SR, et al. Interleukin-10 in the brain. Crit. Rev. Immunol. 21, 427-449 (2001). (Pubitemid 34259914)
190. LeWitt PA. Deprenyl's effect at slowing progression of Parkinsonian disability: the DATATOP study. The Parkinson Study Group. Acta Neurol. Scand. Suppl. 136, 79-86 (1991).
191. Mandel SA, Sagi Y, Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem. Res. 32, 1694-1699 (2007). (Pubitemid 47428857)
192. Mandel S, Maor G, Youdim MB. Iron and a-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin- 3-gallate. J. Mol. Neurosci. 24, 401-416 (2004). (Pubitemid 41389377)
193. Zhu W, Xie W, Pan T, et al. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 21, 3835-3844 (2007). (Pubitemid 350232341)
194. Zhu W, Xie W, Pan T, et al. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J. Neurochem. 105, 1970-1978 (2008). (Pubitemid 351678517)
195. Weinreb O, Amit T, Bar-Am O, Youdim MB. Rasagiline; a novel anti- Parkinsonian monoamine oxidase-b inhibitor with neuroprotective activity. Prog. Neurobiol. 2010).
196. Weinreb O, Amit T, Sagi Y, Drigues N, Youdim MB. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain. J. Neural Transm. 116, 1457-1472 (2009).
197. Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25, 35-44 (2007). (Pubitemid 44765215)
198. Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. NY Acad. Sci. 1122, 155-168 (2007). (Pubitemid 350249546)
199. Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, Youdim MB. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J. Neural Transm. Suppl. (70), 457-465 (2006). (Pubitemid 44622238)
200. Ton TG, Heckbert SR, Longstreth WT, et al. Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Mov. Disord. 21, 964-969 (2006). (Pubitemid 44184597)
201. Gagne JJ, Power MC. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74, 995-1002 (2010).
202. Arib O, Rat P, Molimard R, Chait A, Faure P, de Beaurepaire R. Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons. Eur. J. Pharmacol. 629, 47-52 (2010).
203. Ruiz-Durantez E, Ruiz-Ortega JA, Pineda J, Ugedo L. Stimulatory effect of harmane and other b-carbolines on locus coeruleus neurons in anaesthetized rats. Neurosci. Lett. 308, 197-200 (2001). (Pubitemid 32710157)
204. Abe A, Yamada H. Harmol induces apoptosis by caspase-8 activation independently of Fas/Fas ligand interaction in human lung carcinoma H596 cells. Anticancer Drugs 20, 373-381 (2009).
205. Herraiz T, Gonzalez D, Ancin-Azpilicueta C, Aran VJ, Guillen H. b-carboline alkaloids in Peganum harmala and inhibition of human monoamine oxidase (MAO). Food Chem. Toxicol. 48, 839-845 (2010).